$2.56 Billion is the total value of Tekla Capital Management LLC's 166 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 32.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMGN | Buy | Amgen Inc. | $136,883,989 | +1.8% | 616,539 | +10.9% | 5.36% | +4.7% |
| REGN | Buy | Regeneron Pharmaceuticals, Inc. | $115,985,290 | -1.3% | 161,418 | +12.8% | 4.54% | +1.4% |
| MRK | Buy | Merck & Co., Inc. | $84,021,690 | +43.0% | 728,154 | +31.9% | 3.29% | +47.0% |
| ABBV | Buy | AbbVie Inc. | $73,512,595 | -9.8% | 545,629 | +6.7% | 2.88% | -7.3% |
| BIIB | Buy | Biogen Inc. | $70,626,564 | +5.4% | 247,943 | +2.9% | 2.76% | +8.4% |
| TMO | Buy | Thermo Fisher Scientific Inc. | $51,646,467 | -4.4% | 98,987 | +5.6% | 2.02% | -1.7% |
| MRNA | Buy | Moderna, Inc. | $41,758,943 | -15.6% | 343,695 | +6.7% | 1.63% | -13.3% |
| BSX | Buy | Boston Scientific Corp. | $35,579,861 | +25.7% | 657,790 | +16.2% | 1.39% | +29.1% |
| DHR | Buy | Danaher Corp. | $34,275,120 | +28.7% | 142,813 | +35.1% | 1.34% | +32.2% |
| SYK | Buy | Stryker Corp. | $24,751,342 | +21.1% | 81,128 | +13.3% | 0.97% | +24.6% |
| IQV | Buy | IQVIA Holdings Inc. | $24,528,925 | +95.4% | 109,129 | +72.9% | 0.96% | +100.8% |
| NVO | Buy | Novo Nordisk A/Ssponsored adr | $19,869,002 | +12.2% | 122,777 | +10.3% | 0.78% | +15.4% |
| EW | Buy | Edwards Lifesciences Corp. | $17,884,685 | +26.3% | 189,597 | +10.8% | 0.70% | +29.9% |
| APLS | Buy | Apellis Pharmaceuticals, Inc. | $15,782,893 | +77.1% | 173,248 | +28.2% | 0.62% | +82.3% |
| BAX | Buy | Baxter International, Inc. | $14,778,297 | +441.3% | 324,370 | +381.9% | 0.58% | +455.8% |
| KRTX | Buy | Karuna Therapeutics, Inc. | $12,702,422 | +30.8% | 58,577 | +9.6% | 0.50% | +34.3% |
| PODD | New | Insulet Corp. | $12,642,844 | – | 43,847 | +100.0% | 0.50% | – |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $12,387,097 | -6.7% | 138,791 | +12.1% | 0.48% | -4.0% |
| THC | New | Tenet Healthcare Corp. | $12,131,317 | – | 149,070 | +100.0% | 0.48% | – |
| PCVX | Buy | Vaxcyte, Inc. | $9,699,946 | +5076.1% | 194,232 | +3784.6% | 0.38% | +5328.6% |
| MDGL | Buy | Madrigal Pharmaceuticals, Inc. | $7,954,254 | +163.1% | 34,434 | +175.9% | 0.31% | +170.4% |
| HZNP | New | Horizon Therapeutics plc | $7,448,911 | – | 72,425 | +100.0% | 0.29% | – |
| INSP | New | Inspire Medical Systems, Inc. | $7,147,924 | – | 22,018 | +100.0% | 0.28% | – |
| MEDP | Buy | Medpace Holdings, Inc. | $6,464,896 | +264.4% | 26,918 | +185.3% | 0.25% | +272.1% |
| IMVT | Buy | Immunovant, Inc. | $6,377,714 | +256.3% | 336,200 | +191.3% | 0.25% | +267.6% |
| KDNY | Buy | Chinook Therapeutics, Inc. | $5,796,156 | +199.8% | 150,863 | +80.7% | 0.23% | +206.8% |
| LIVN | Buy | LivaNova plc | $5,579,126 | +100.4% | 108,480 | +69.8% | 0.22% | +105.7% |
| RETA | Buy | Reata Pharmaceuticals, Inc. Class Aclass a | $3,492,130 | +115.2% | 34,250 | +91.9% | 0.14% | +121.0% |
| AKRO | New | Akero Therapeutics, Inc. | $2,871,295 | – | 61,497 | +100.0% | 0.11% | – |
| PHG | Buy | Koninklijke Philips N.V.ny reg shares | $2,489,253 | +23.5% | 114,765 | +4.5% | 0.10% | +26.0% |
| New | Amylyx Pharmaceuticals, Inc. | $2,243,431 | – | 104,007 | +100.0% | 0.09% | – | |
| TCMD | Buy | Tactile Systems Technology, Inc. | $1,457,707 | +157.8% | 58,472 | +69.8% | 0.06% | +159.1% |
| XNCR | New | Xencor, Inc. | $1,415,175 | – | 56,675 | +100.0% | 0.06% | – |
| MOR | Buy | MorphoSys AGsponsored ads | $1,323,617 | +309.3% | 177,191 | +116.4% | 0.05% | +333.3% |
| ZNTL | New | Zentalis Pharmaceuticals, Inc. | $1,132,801 | – | 40,156 | +100.0% | 0.04% | – |
| FULC | Buy | Fulcrum Therapeutics, Inc. | $847,730 | +408.1% | 256,888 | +338.8% | 0.03% | +450.0% |
| New | HilleVax, Inc. | $464,130 | – | 27,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.